At the end of the first quarter of this year, several active equity funds with heavy holdings in the humanoid robot sector were still far ahead in performance, while recently, funds with heavy holdings in the innovative medicine sector have stood out. As of April 27th, the Huitianfu Hong Kong Advantage Selection Hybrid (QDII) A managed by fund manager Zhang Wei has become the best performing public offering product of the year with a return rate of 64.44%. Industry insiders have stated that compared to the past, the market for innovative drugs in this round is more rational. Firstly, the industry trends and policy guidance have become clearer, leading to an increase in market confidence; Secondly, many key companies’ core products have already been listed or validated with critical clinical data, resulting in a significant increase in investment success rates; Thirdly, some leading companies are about to cross the ...
NO.1 clarifies for the first time to crack down on online “medical trusts” The National Center for Disease Control and Prevention and three other departments recently jointly released the “2025 National Random Supervision and Sampling Plan” for the medical and health field. Compared with the 2024 plan, the 2025 plan will make adjustments in the scope of supervision, add new areas of supervision such as Internet diagnosis and treatment, mental health, and for the first time explicitly crack down on new illegal behaviors such as online “medical care”, further strengthen the governance of public health and medical order. Comment: The clear crackdown on online “medical trusts” in regulation is a powerful upgrade to medical supervision. The concealment of online “medical care” is strong, seriously disrupting medical order and damaging patient rights. It is expected to purify the medical network space with the supervision of new fields such as Internet ...
Organiser:Asociación Médica de México (Mexican Medical Association), Informa Markets Time:August 19–21, 2025 address:Av. del Conscripto 311, Lomas de Sotelo, Hipódromo de las Américas, Miguel Hidalgo, 11610 Ciudad de México, CDMX, Mexico Exhibition hall:Centro Banamex Product range: Medical Devices: Medical equipment, laboratory equipment and supplies, testing, analysis, and diagnostic instruments with accessories, radiology, imaging, ultrasound devices, electronic medical instruments, physiotherapy and rehabilitation products, surgical and aesthetic technologies, monitoring instruments, ophthalmic equipment, dental equipment, medical furniture, medical consumables, and hospital facilities. Medical-Related Products: Safety and security equipment for medical use, medical gases, information technology, software, adult products, pharmaceuticals, etc. About EXPOMED: EXPOMED, the Mexico Medical Equipment Exhibition, stands as Mexico’s premier and most comprehensive industry event for medical supplies and pharmaceutical equipment. The exhibition will bring together medical professionals, manufacturers, and distributors from around the globe, including attendees from hospitals, clinics, pharmacies, and more, offering exhibitors a highly specialized platform ...
According to the official website of the World Health Organization (WHO) on April 24th, during the “World Immunization Week” held from the 24th to the 30th, WHO、 The United Nations Children’s Fund and the Global Alliance for Vaccines and Immunization have jointly issued a warning that diseases that could have been prevented by vaccines, such as measles, meningitis, and yellow fever, are on the rise globally due to the spread of misinformation and reduced international aid. These three major international organizations urgently call on countries to continue investing political attention and funding to consolidate the achievements of immunization programs and safeguard the significant progress made globally in reducing child mortality rates over the past half century. The latest monitoring data shows that since 2021, the number of measles cases has been increasing year by year. By 2023, the number of cases will reach 10.3 million, an increase of 20% ...
Hepalink announced on the evening of April 24 that its wholly-owned subsidiary Tiandao Pharmaceutical recently received an approval notice for Enoxaparin Sodium Injection issued by the South African Health Products Administration. The drug can be used before and after surgery to prevent or prevent blood clots in the blood. This approval means that Hepalink’s Enoxaparin Sodium preparations can be sold in the South African market. Hepalink disclosed its first quarter report for 2025 on the same day, with a net profit attributable to shareholders of 157 million yuan in the first quarter, a year-on-year increase of 1%. https://finance.eastmoney.com/a/202504243387456384.html
A new study published in the Journal of the American Medical Association on April 24 showed that at the current measles vaccination rate in the U.S., more than 850,000 new measles cases may occur in the U.S. in the next 25 years, and measles may resurge. A team led by researchers at Stanford University used a model to assess the spread of vaccine-preventable infectious diseases in the U.S., and predicted the infection rate and number of infectious diseases, including measles, rubella, polio and diphtheria, under different vaccination rates in the next 25 years. The model predicts that at the current state-level vaccination rate, the U.S. is expected to have 851,300 new measles cases in the next 25 years; if the vaccination rate drops by 10%, it is expected that the number of new measles cases in this period will reach 11.1 million; if the vaccination rate increases by 5%, it ...
Drugdu.com expert’s response: The U.S. Food and Drug Administration (FDA) plans to gradually terminate the requirement for animal testing of monoclonal antibodies, primarily based on the following aspects: I. Technological Advancements Offer Alternative Approaches Organoids and Organ-on-a-Chip Technology: These technologies can simulate the physiological functions of human organs, demonstrating high predictability in drug safety testing. For example, liver-on-a-chip models have achieved up to 87% accuracy in predicting drug-induced liver toxicity. Artificial Intelligence and Computational Models: By simulating drug absorption, distribution, metabolism, and excretion (ADME) in the human body, AI models can more accurately predict drug efficacy and toxicity, reducing reliance on animal experiments. Real-World Data: Leveraging existing real-world safety data from other countries to further validate drug performance in humans provides a more reliable basis for drug assessment. II. Limitations of Animal Experiments Species Differences: Animal models exhibit significant physiological and metabolic disparities from humans, making it difficult to extrapolate ...
Recently, Shenzhen Baotekang Biotechnology Co., Ltd. was established, with Zhao Yanqing as the legal representative and a registered capital of 1 million yuan. Its business scope includes: manufacturing of bio-based materials; sales of bio-based materials; sales of sanitary products and disposable medical products; retail of cosmetics, etc. According to the equity penetration of Qichacha, the company is wholly owned by Sinovac Biotech. https://finance.eastmoney.com/a/202504243387405326.html
On April 24, according to Kangle GuardAccording to the news, its holding subsidiary, Kangleweishi (Kunming) Biotechnology Co., Ltd., received the “Acceptance Notice” (Acceptance No.: CXSS2500048) issued by the Center for Drug Evaluation (CDE) of the State Drug Administration. The company’s independently developed recombinant trivalent human papillomavirus (16/18/58) vaccine (Escherichia coli) (referred to as “trivalent HPV vaccine”) marketing authorization application was accepted by CDE. The trivalent HPV vaccine independently developed by Kangleweishi is mainly used to prevent persistent infection of HPV 16/18/58 and the resulting precancerous lesions and cervical cancer and other diseases. https://finance.eastmoney.com/a/202504243387405326.html
Hepalink announced on the evening of April 24 that its wholly-owned subsidiary Tiandao Pharmaceutical recently received an approval notice for enoxaparin sodium injection issued by the South African Health Products Administration. The drug can be used before and after surgery to prevent or prevent blood clots in the blood. This approval means that Hepalink’s enoxaparin sodium preparations can be sold in the South African market. Hepalink disclosed its first quarter report for 2025 on the same day, with a net profit attributable to shareholders of RMB 157 million in the first quarter, a year-on-year increase of 1%. https://finance.eastmoney.com/a/202504243387396772.html
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.